title: Marked increase of CD8+S6F1+ and CD8+CD57+ cells in patients with graft-versus-host disease after allogeneic bone marrow transplantation.
abstract: Peripheral blood lymphocytes (PBL) from 24 allogeneic bone marrow transplant (BMT) recipients were studied serially using flow cytometry and two-color analysis. Dual labelling with two monoclonal antibodies (moAbs), CD8/S6F1 (CD11a) and CD8/CD57 was used to analyze the surface phenotypes of PBL after allogeneic BMT. In patients with acute and chronic GVHD, CD8+S6F1+ cells were markedly increased from the onset of GVHD and recovered to normal range 6 years after transplantation. By contrast, CD8+S6F1- cells fell below normal range and remained markedly decreased for 2-3 years after transplantation in patients with acute and chronic GVHD. A slight but significant increase of CD8+CD57- cells was observed with clinical signs of acute GVHD. On the other hand, CD8+CD57+ cells were increased after the onset of acute and chronic GVHD and recovered to normal range 6 years after transplantation. These results suggest that these subsets of CD8+ cells may play important roles in the pathophysiology of GVHD.
authors.affiliation: Department of Cancer Chemotherapy, Center for Adult Diseases, Osaka, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Fukuda
authors.forename: H
authors.initials: H
authors.lastname: Nakamura
authors.forename: N
authors.initials: N
authors.lastname: Tominaga
authors.forename: H
authors.initials: H
authors.lastname: Teshima
authors.forename: A
authors.initials: A
authors.lastname: Hiraoka
authors.forename: H
authors.initials: H
authors.lastname: Shibata
authors.forename: T
authors.initials: T
authors.lastname: Masaoka
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000032:analysis* / Q000276:immunology; D015703:Antigens, CD / Q000032:analysis* / Q000276:immunology; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis* / Q000276:immunology; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000276:immunology; D018845:CD11 Antigens; D018959:CD57 Antigens; D016827:CD8 Antigens / Q000032:analysis* / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D006086:Graft vs Host Disease / Q000276:immunology* / Q000473:pathology* / Q000503:physiopathology; D006801:Humans; D016131:Lymphocyte Subsets / Q000276:immunology / Q000473:pathology / Q000502:physiology; D008214:Lymphocytes / Q000276:immunology* / Q000473:pathology* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D018845:CD11 Antigens; D018959:CD57 Antigens; D016827:CD8 Antigens